1 min read
Neumora Posts $0.18 Q3 GAAP Loss Per Share and $85.7 Million in Cash
Cash and cash equivalents totaled $85.7 million as of Sept. 30, 2026. The company provided no updated financial runway guidance.
Neumora Therapeutics, Inc. posted a GAAP loss of $0.18 per share for the third quarter of 2026, with cash and cash equivalents totaling $85.7 million as of Sept. 30.
The company provided no updated financial runway guidance.